vs
NATIONAL RESEARCH CORP（NRC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是NATIONAL RESEARCH CORP的1.0倍（$35.5M vs $35.2M），NATIONAL RESEARCH CORP净利率更高（5.1% vs -304.2%，领先309.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -4.6%），NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -0.2%）
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NRC vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.0倍
$35.2M
营收增速更快
RXRX
高出686.4%
-4.6%
净利率更高
NRC
高出309.3%
-304.2%
自由现金流更多
NRC
多$53.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $35.5M |
| 净利润 | $1.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 13.3% | -304.8% |
| 净利率 | 5.1% | -304.2% |
| 营收同比 | -4.6% | 681.7% |
| 净利润同比 | -72.6% | 39.6% |
| 每股收益（稀释后） | $49.58 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRCRXRX
| Q4 25 | $35.2M | $35.5M | ||
| Q3 25 | $34.6M | $5.2M | ||
| Q2 25 | $34.0M | $19.2M | ||
| Q1 25 | $33.6M | $14.7M | ||
| Q4 24 | $36.9M | $4.5M | ||
| Q3 24 | $35.8M | $26.1M | ||
| Q2 24 | $35.0M | $14.4M | ||
| Q1 24 | $35.3M | $13.8M |
净利润NRCRXRX
| Q4 25 | $1.8M | $-108.1M | ||
| Q3 25 | $4.1M | $-162.3M | ||
| Q2 25 | $-106.0K | $-171.9M | ||
| Q1 25 | $5.8M | $-202.5M | ||
| Q4 24 | $6.6M | $-178.9M | ||
| Q3 24 | $5.7M | $-95.8M | ||
| Q2 24 | $6.2M | $-97.5M | ||
| Q1 24 | $6.4M | $-91.4M |
毛利率NRCRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率NRCRXRX
| Q4 25 | 13.3% | -304.8% | ||
| Q3 25 | 22.4% | -3327.6% | ||
| Q2 25 | 4.7% | -916.8% | ||
| Q1 25 | 25.6% | -1297.9% | ||
| Q4 24 | 26.0% | -4042.4% | ||
| Q3 24 | 22.3% | -377.1% | ||
| Q2 24 | 25.3% | -697.4% | ||
| Q1 24 | 24.8% | -698.4% |
净利率NRCRXRX
| Q4 25 | 5.1% | -304.2% | ||
| Q3 25 | 11.9% | -3135.3% | ||
| Q2 25 | -0.3% | -894.2% | ||
| Q1 25 | 17.2% | -1373.3% | ||
| Q4 24 | 17.8% | -3935.5% | ||
| Q3 24 | 15.9% | -367.5% | ||
| Q2 24 | 17.6% | -676.6% | ||
| Q1 24 | 18.0% | -662.4% |
每股收益（稀释后）NRCRXRX
| Q4 25 | $49.58 | $-0.17 | ||
| Q3 25 | $0.18 | $-0.36 | ||
| Q2 25 | $-0.01 | $-0.41 | ||
| Q1 25 | $0.25 | $-0.50 | ||
| Q4 24 | $0.27 | $-0.56 | ||
| Q3 24 | $0.24 | $-0.34 | ||
| Q2 24 | $0.26 | $-0.40 | ||
| Q1 24 | $0.27 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $14.0M | $1.1B |
| 总资产 | $134.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资NRCRXRX
| Q4 25 | $4.1M | $743.3M | ||
| Q3 25 | $2.2M | $659.8M | ||
| Q2 25 | $5.3M | $525.1M | ||
| Q1 25 | $2.5M | $500.5M | ||
| Q4 24 | $4.2M | $594.4M | ||
| Q3 24 | $3.5M | $427.6M | ||
| Q2 24 | $485.0K | $474.3M | ||
| Q1 24 | $1.7M | $296.3M |
总债务NRCRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $48.7M | $20.5M | ||
| Q2 24 | $33.3M | $22.9M | ||
| Q1 24 | $35.2M | — |
股东权益NRCRXRX
| Q4 25 | $14.0M | $1.1B | ||
| Q3 25 | $14.3M | $1.0B | ||
| Q2 25 | $21.3M | $919.1M | ||
| Q1 25 | $29.7M | $933.9M | ||
| Q4 24 | $31.3M | $1.0B | ||
| Q3 24 | $34.6M | $524.6M | ||
| Q2 24 | $40.2M | $584.4M | ||
| Q1 24 | $36.9M | $401.2M |
总资产NRCRXRX
| Q4 25 | $134.9M | $1.5B | ||
| Q3 25 | $135.7M | $1.4B | ||
| Q2 25 | $141.4M | $1.3B | ||
| Q1 25 | $135.2M | $1.3B | ||
| Q4 24 | $132.5M | $1.4B | ||
| Q3 24 | $131.8M | $726.5M | ||
| Q2 24 | $119.1M | $775.9M | ||
| Q1 24 | $120.9M | $557.8M |
负债/权益比NRCRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | 1.41× | 0.04× | ||
| Q2 24 | 0.83× | 0.04× | ||
| Q1 24 | 0.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $6.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 17.2% | -133.1% |
| 资本支出强度资本支出/营收 | 3.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.99× | — |
| 过去12个月自由现金流最近4个季度 | $15.7M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流NRCRXRX
| Q4 25 | $7.2M | $-46.1M | ||
| Q3 25 | $13.8M | $-117.4M | ||
| Q2 25 | $-1.1M | $-76.4M | ||
| Q1 25 | $6.6M | $-132.0M | ||
| Q4 24 | $6.4M | $-115.4M | ||
| Q3 24 | $9.4M | $-59.2M | ||
| Q2 24 | $6.8M | $-82.2M | ||
| Q1 24 | $12.0M | $-102.3M |
自由现金流NRCRXRX
| Q4 25 | $6.1M | $-47.3M | ||
| Q3 25 | $10.2M | $-117.6M | ||
| Q2 25 | $-4.1M | $-79.6M | ||
| Q1 25 | $3.7M | $-133.8M | ||
| Q4 24 | $1.9M | $-116.7M | ||
| Q3 24 | $7.8M | $-63.8M | ||
| Q2 24 | $1.5M | $-83.4M | ||
| Q1 24 | $7.9M | $-109.0M |
自由现金流率NRCRXRX
| Q4 25 | 17.2% | -133.1% | ||
| Q3 25 | 29.4% | -2272.5% | ||
| Q2 25 | -12.2% | -413.9% | ||
| Q1 25 | 10.9% | -907.4% | ||
| Q4 24 | 5.2% | -2567.7% | ||
| Q3 24 | 21.8% | -244.6% | ||
| Q2 24 | 4.3% | -578.5% | ||
| Q1 24 | 22.4% | -789.9% |
资本支出强度NRCRXRX
| Q4 25 | 3.2% | 3.5% | ||
| Q3 25 | 10.4% | 4.7% | ||
| Q2 25 | 8.8% | 16.4% | ||
| Q1 25 | 8.9% | 12.4% | ||
| Q4 24 | 12.0% | 28.6% | ||
| Q3 24 | 4.5% | 17.5% | ||
| Q2 24 | 15.0% | 8.2% | ||
| Q1 24 | 11.7% | 48.2% |
现金转化率NRCRXRX
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
